Belle Mead, NJ, United States of America

Karel F Bernady

This inventor holds 27 USPTO granted patents, primarily in Prostanoic Acid Derivatives. Top assignee: American Cyanamid Company. Active years: 1976-1986.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Karel F Bernady. Retrieved from https://idiyas.com/inventor/karel-f-bernady

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27

% Patents Active = 100.0

Average Co-Inventor Count = 3.5

ph-index = 6

Forward Citations = 101(Granted Patents)

Location History:

South Sommerville, NJ (US) (1979 - 1981)
Somerville, NJ (US) (1980 - 1981)
South Summerville, NJ (US) (1981)
Suffern, NY (US) (1976 - 1982)
Belle Mead, NJ (US) (1978 - 1986)

Company Filing History:

27 out of 3,580

American Cyanamid Company

patents

Years Active: 1976-1986

Loading Chart...

Areas of Expertise:

Prostanoic Acids

Epoxycyclopentanones

Hydroxy Substituted

Esters

Amide Derivatives

Alkoximino Compounds

Triphenylmethoxy

N-Alkylethylenediamines

Cyclopentenes

Novel Derivatives

Carboxyhexyl

Lithium Compounds

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 4610822 - Process for preparing 6-[D(-)-.alpha.-(4-C.sub.1 (1986-09-09),

2. 4439365 - Novel hydroxy substituted prostanoic acids, esters, congeners, (1984-03-27),

3. 4343949 - Novel 2-substituted-3,4-epoxycyclopentan-1-ones, (1982-08-10),

4. 4293704 - Novel 2-substituted-3,4-epoxycyclopentan-1-ones, (1981-10-06),

5. 4245121 - Prostenoic acids and esters (1981-01-13),

6. 4243817 - Prostenoic acids and esters (1981-01-06),

7. 4237316 - Novel 2-substituted-3,4-epoxycyclopentan-1-ones, (1980-12-02),

8. 4217308 - Process for preparing N-alkylethylenediamines (1980-08-12),

9. 4202988 - Prostenoic acids and esters (1980-05-13),

10. 4197407 - Prostenoic acids and esters (1980-04-08),

11. 4179574 - Novel 2-substituted-3,4-epoxycyclopentan-1-ones, (1979-12-18),

12. 4178456 - Prostenoic acids and esters (1979-12-11),

13. 4140715 - Process for preparing N-(1,1-dimethyl-3-oxobutyl)acrylamide from a (1979-02-20),

14. 4140714 - Process for preparing N-(1,1-dimethyl-3-oxobutyl)acrylamide from a (1979-02-20),

15. 4123456 - Novel 11-hydroxy-9-keto-5,6-cis-13,14-cis-prostadienoic acid derivatives (1978-10-31),

Title: Karel F. Bernady: A Pioneer in Pharmaceutical Innovations

Introduction

Karel F. Bernady, based in Belle Mead, NJ, is a prominent inventor recognized for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 27 patents, Bernady has established himself as a leading figure in the development of innovative compounds and processes that have advanced medical treatments.

Latest Patents

Among his latest patents are two noteworthy innovations: a process for preparing 6-[D(-)-α-(4-C1 - alkyl-2,3-dioxo)]-piperazinocarbonylamino)phenylacetamid o]penicillanic acids and related pharmaceutically acceptable salts, and novel hydroxy substituted prostanoic acids. The latter includes certain 11-hydroxy and 11-deoxy-9-keto (or hydroxy)-prostanoic acid derivatives, which are potentially valuable as bronchodilators, anti-ulcer agents, or intermediates in further pharmaceutical development.

Career Highlights

Karel F. Bernady works at the American Cyanamid Company, a well-respected organization in the pharmaceutical industry. His career is marked by a commitment to innovation and a deep understanding of chemical processes that lead to effective medical solutions. His extensive patent portfolio underscores his importance in the advancement of pharmaceutical applications.

Collaborations

Throughout his career, Bernady has collaborated with esteemed co-inventors, including Martin J. Weiss and John F. Poletto. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the quality and applicability of their innovations in the pharmaceutical domain.

Conclusion

Karel F. Bernady stands out as a significant contributor to the field of pharmaceuticals through his inventive spirit and collaborative efforts. His dedication to advancing healthcare solutions reflects a profound commitment to innovation and the betterment of human health. As he continues to develop groundbreaking processes and compounds, the impact of his work will undoubtedly resonate within the industry for years to come.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]